Navigation Links
Presentations at American College of Cardiology Meeting Highlight,New Opportunities for HDL Therapy

se atherosclerosis, a systemic disease of the blood vessels caused by the build-up of cholesterol-filled plaques in the vascular system and, most critically, in the coronary arteries. Regression of such plaques may have a major impact on reducing the risk of acute coronary events. The Company's Viral Immunotherapy platform focuses on the removal of the lipid coatings from lipid-enveloped viruses and other lipid-containing infectious agents by applying Lipid Sciences' proprietary delipidation technologies. The Company believes that removing the virus' protective lipid coating enhances the processing and presentation of viral proteins to stimulate the body's immune system to effectively fight the disease. Conditions that could potentially be impacted by these technologies include HIV, Hepatitis B and Hepatitis C, West Nile, SARS, influenza, and a broad range of animal health applications.

Forward-Looking Statements: This release contains forward-looking statements concerning plans, objectives, goals, strategies, study results, anticipations, expectations, future events or performance as well as all other statements that are not statements of historical fact. The forward-looking statements contained in this release reflect our current beliefs and expectations on the date of this release. Actual results, performance or outcomes may differ materially from what is expressed in the forward-looking statements. Readers are referred to the documents filed by us with the SEC, specifically the most recent reports on Form 10-K and Form 10-Q which identify important risk factors that could cause actual results to differ from those contained in the forward-looking statements. In addition to those risk factors, other factors that could cause actual results to differ materially include the following: Our inability to obtain adequate funds; the significant losses we have incurred to date, and our expectation that we will incur substantial losses in the future; the failure of o
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
2. Nuvelo Announces Presentations on rNAPc2 and NU172 at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
4. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Mechanism of Action and Clinical Activity of Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American Diabetes Association 67th Scientific Sessions in Chicago, Illinois
5. Inspire Announces Presentations at Two European Scientific Conferences
6. Presentations at 2007 European Stroke Congress Highlights New Direction for Viprinex (ancrod)
7. IDM Pharma Announces UVIDEM(R) and EP-2101 Data Presentations at 2007 ASCO Annual Meeting
8. MedImmune Highlights Advances in Inflammatory Disease Pipeline With Series of Data Presentations
9. Pharmacyclics Announces Presentations and Published Abstracts on Xcytrin at The 2007 American Society of Clinical Oncology Annual Meeting
10. Schering-Plough Announces Hepatitis C Data Presentations at Digestive Disease Week (DDW) 2007 Annual Meeting
11. Lux Biosciences Investigational Therapy for Uveitis, LX211, is Subject of Two Presentations at Key Ophthalmology Meeting, ARVO 2007
Post Your Comments:
(Date:10/22/2014)... and AUSTIN, Texas , ... PureMHC LLC today announced they have entered into ... antibody-based immunotherapies designed to target cancers. ... peptides displayed on the surfaces of tumor cells ... targets (PTTs), derived from proteins that play a ...
(Date:10/22/2014)... -- Recently published clinical studies of Stretta for gastroesophageal reflux ... evidence. This data has led to significantly expanded insurance ... sufferers of refractory GERD. The substantial ... as a safe and effective GERD treatment has driven ... nearly 50 million Americans. The new clinical studies include; ...
(Date:10/20/2014)... MOUNTAIN VIEW, Calif. , Oct. 20, 2014 /PRNewswire/ ... field of interventional pulmonology, today announced completion of enrollment ... schedule.  The RENEW Clinical Study is the FDA-approved IDE ... treatment for severe emphysema. It was anticipated ... US in February 2013, would take until the end ...
Breaking Medicine Technology:Biotech Companies To Co-Discover And Co-Develop Antibodies Targeting Novel Phosphopeptide Tumor Targets 2Recent Clinical Study Data Confirms Efficacy of Stretta Therapy - Spurs Additional Insurance Coverage and Financing Round 2PneumRx Completes RENEW Pivotal Trial Enrollment 2PneumRx Completes RENEW Pivotal Trial Enrollment 3
... Inc. (Nasdaq: MSON ), a developer of minimally invasive ... the ablation of tumors and worldwide for other acute health ... year ended June 30, 2009. , The Company also reported ... payment of $3.5 million was received on April 7, 2009 ...
... , SAN MATEO, Calif., Oct. 1 Corthera Inc. ... (FDA) has granted Fast Track designation to relaxin, the ... failure (AHF). The Fast Track program facilitates the development ... treat serious or life-threatening conditions and that demonstrate the ...
Cached Medicine Technology:Misonix Reports Fourth Quarter and Fiscal Year 2009 Financial Results 2Misonix Reports Fourth Quarter and Fiscal Year 2009 Financial Results 3Misonix Reports Fourth Quarter and Fiscal Year 2009 Financial Results 4Misonix Reports Fourth Quarter and Fiscal Year 2009 Financial Results 5Misonix Reports Fourth Quarter and Fiscal Year 2009 Financial Results 6Misonix Reports Fourth Quarter and Fiscal Year 2009 Financial Results 7Misonix Reports Fourth Quarter and Fiscal Year 2009 Financial Results 8Misonix Reports Fourth Quarter and Fiscal Year 2009 Financial Results 9Misonix Reports Fourth Quarter and Fiscal Year 2009 Financial Results 10Corthera's Relaxin Receives FDA Fast Track Designation for the Treatment of Acute Heart Failure 2Corthera's Relaxin Receives FDA Fast Track Designation for the Treatment of Acute Heart Failure 3
(Date:10/22/2014)... Hay House is pleased to announce the official ... Life (Paperback; $10.82) written by the highly esteemed Tommy Rosen, ... book is meant to help readers of all kinds end ... , Recovery 2.0 is not the average self-help book, or ... guide for what comes next. For many, Alcoholics ...
(Date:10/22/2014)... Healthcare professionals who are looking for ... home or on-the-go via laptops, tablets or mobile ... premium Seminar-on-Demand CE courses. The new courses add ... hours of CE course offerings, allowing therapy ... such a diverse library, there’s something for everyone. ...
(Date:10/22/2014)... October 22, 2014 Richard Carlson, Managing ... industry leader with over 25 years experience. Mr. ... in the areas related to EDI, B2B Commerce, RFID ... an Editorial Advisory Board member for Pharmaceutical Commerce Magazine ... Blue Fin Group is a management and technology consulting ...
(Date:10/22/2014)... 21, 2014 (HealthDay News) -- Two sisters in high ... damage. Ilina and Medha Krishen use electronic stethoscopes, ... of trouble in breathing patterns or heartbeats. Ilina, ... Michigan, wanted to find a way to detect early ... Using an electronic stethoscope, Ilina recorded one breath cycle ...
(Date:10/22/2014)... HealthDay Reporter , MONDAY, Oct. ... officially tightened guidelines for health workers treating Ebola patients, now ... of a respirator at all times. The U.S. Centers ... rules after two Dallas nurses contracted Ebola while caring for ... national Thomas Eric Duncan. Nina Pham is currently being treated ...
Breaking Medicine News(10 mins):Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 2Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 3Health News:Top Provider of Continuing Education at Home Releases 20 New Online Courses 2Health News:Rich Carlson and Marc Duey to Hold Workshop at CBI’s Specialty Pharmacy and Distribution Networks Conference 2Health News:Teen Sisters Develop Ways to Measure Lung, Heart Damage 2Health News:CDC Tightens Rules on Caring for Ebola Patients 2Health News:CDC Tightens Rules on Caring for Ebola Patients 3
... sees telcos looking to find,viable solutions for improving public safety and network resiliency for all ... Americans, BOULDER, Colo., April 3, 2008 , WHO: ... Aztek Networks ( http://www.azteknetworks.net ), ... 20 years experience, Bruny has served as CEO of Aztek Networks, ...
... Rhytec, Inc. the pioneer,of plasma skin regeneration ... a novel thermal energy called plasma for reversing ... U.S. Food and Drug Administration (FDA),clearance to market ... is already cleared by the FDA for treating ...
... a,statement of William V. Corr, Executive Director, Campaign for ... broken Ohio,s,promise to protect its kids from tobacco by ... tobacco prevention program, run by the,Ohio Tobacco Prevention Foundation. ... carried out. More kids will become addicted to tobacco, ...
... Grubb &,Ellis Healthcare REIT, Inc. today announced the acquisition ... 3035, 3037, 3131, and 3133 Lakeland Hills Blvd., the ... buildings. Each,building has approximately 8,000 square feet of gross ... 1998 on approximately 4.64,acres, the buildings are cumulatively 90 ...
... Roy Blunt (Mo.) issued the following statement today after ... global AIDS initiative -,even though the president himself only ... the program couldn,t spend in 10,years what the majority ... more than one occasion that the president,s initiative on,fighting ...
... Disease Patients Rising, CHICAGO, April 2 ... disease and, according to the latest research,from Prevent ... number,is continuing to climb. With more than 130 ... million suffer from leading causes of vision loss ...
Cached Medicine News:Health News:Telecommunications Carriers Respond To Congress' Declaration of April as National 9-1-1 Education Month 2Health News:Telecommunications Carriers Respond To Congress' Declaration of April as National 9-1-1 Education Month 3Health News:Portrait(R) Plasma Receives Clearance from the FDA to Treat Acne Scars 2Health News:Portrait(R) Plasma Receives Clearance from the FDA to Treat Acne Scars 3Health News:Gov. Strickland, Legislative Leaders Break Promise to Protect Ohio's Kids from Tobacco 2Health News:Grubb & Ellis Healthcare REIT Acquires Vista Professional Center in Lakeland, Fla. 2Health News:Grubb & Ellis Healthcare REIT Acquires Vista Professional Center in Lakeland, Fla. 3Health News:Grubb & Ellis Healthcare REIT Acquires Vista Professional Center in Lakeland, Fla. 4Health News:Eye Disease Continuing to Increase Among Americans 2Health News:Eye Disease Continuing to Increase Among Americans 3
... Flexible excellence for patients and clinicians., ... Aestiva/5 anesthesia system, the Aestiva/5 MRI is ... systems with a fully functional, integrated ventilator. ... Gauss, 1.5 T active shielded magnet), the ...
... ventilator control panel is conveniently located on the ... angle whether standing or sitting. The ventilator control ... and numerics. The ventilator has CMV, PCV and ... available in two lengths facilitates both the placing ...
... The flexible, modular approach to meeting today's ... offers one of the best ergonomic solutions in ... to operate from any position. A revolving arm ... magazine and moveable patient cassette mean that there ...
... The Narkomed GS provides high quality ... interface. The proven technologies of the ... make the Narkomed GS user-friendly and ... high quality Narkomed GS is the ...
Medicine Products: